Second to skin cancer, prostate cancer is the most common form of cancer in men; approximately 300,000 men in the United States are diagnosed with prostate cancer every year. The exact cause of prostate cancer is unknown. According to the American Cancer Society, an average American man has a one in nine chance of being diagnosed with prostate cancer during his lifetime.
Ideally, seeking a second opinion is worthwhile. Prostate cancer is a complex disease, and physicians may differ in their opinions. Some types of prostate cancer treatment are as follows:
- Seed Brachytherapy
- External Beam Radiation Therapy
- Proton Therapy
- HDR Brachytherapy
- Hormone Therapy and Watchful Waiting
Chicago Prostate Cancer Center specializes in Low Dose Rate Brachytherapy.
What is Brachytherapy for Prostate Cancer?
Brachytherapy, also referred to as seed implants or seeds, brachytherapy is a one-time, minimally invasive procedure usually performed in an outpatient setting under general anesthesia. The procedure itself involves the placement of tiny radioactive seeds inside the prostate using ultrasound equipment.
The seed implants immediately emit radiation and kill the malignant cells inside the prostate. The time it takes for the radiation to deliver its total dose depends on the seed (isotope) used. There are currently 3 isotopes commonly used in prostate brachytherapy: Cesium131, Iodine125, and Palladium103. Brachytherapy seeds themselves are compatible with human tissue. After the procedure, patients are taken to recovery and are typically discharged a few hours later. Most patients resume normal activities within 24-48 hours. The most common side effect of brachytherapy is temporary urinary irritation including frequency and urgency. These symptoms typically last from a few weeks to a few months.
Which Cancer May be Treated with Radiation Delivered by Brachytherapy?
Typically, the best candidate for brachytherapy is someone with a prostate tumor confined to the prostate gland that has a very low risk of spreading to other parts of the body.
Brachytherapy is not appropriate in patients whose cancer has already spread beyond the prostate and into other areas of the body. Patients who have had a transurethral resection of the prostate (TURP) may have brachytherapy, however, they will need to meet certain criteria.
How Successful is Brachytherapy for Prostate Cancer?
Cure rates in low risk patients are equal to or better than surgery or external beam radiation. For intermediate and high-risk patients, brachytherapy combined with EBRT has resulted in superior outcomes when compared to surgery. (1, 2)
What are the Side Effects of Brachytherapy?
With the seed implant, there are no incisions or stitches required such as in the case of surgery. Furthermore, there is minimal, if any, post-operative pain. (3)
When looking at urinary side effects, incontinence rates are usually less than 1% (4). For surgery, rates can be as high as 10% (5).
Approximately 6-25% of patients who receive brachytherapy will experience a decrease in sexual function (6) versus approximately 50% of patients who undergo surgery (7). Erectile medications and other aids have proven to be very effective.
When compared to EBRT, patients undergoing prostate brachytherapy experience much lower rates of bowel irritation with prostate brachytherapy (8).
Blood loss during an implant is minimal when compared to surgery (9).
When compared to prostatectomy (surgical removal) or many weeks of external beam radiation, prostate brachytherapy is the most cost-effective treatment (10).
What are the Advantages of Brachytherapy?
The rise in the number of men diagnosed with prostate cancer has led to a growing need for improved treatment options that can offer excellent cure rates with minimal side effects at a low cost. Brachytherapy has numerous advantages over other treatment options.
Since brachytherapy is an outpatient procedure, no hospital stay is required. Furthermore, the seed implant is complete in one visit whereas a number of months are required to complete a course of external beam radiation. Patients are not required to take weeks off of work such as in surgery. As we see younger and younger patients with full-time jobs, it is important that they do not interrupt their work schedule for a prolonged period of time. Patients are able to resume normal activity within a day.
What to Expect after Brachytherapy
Visit our Prostate Cancer Follow Up page for information around what to expect after Brachytherapy.
World Class Prostate Cancer Treatment in Chicago
Chicago Prostate Cancer Center is committed to providing comprehensive and compassionate treatment for prostate cancer patients using LDR Brachytherapy (radioactive seed implant). We pride ourselves on being a patient-centric facility with experienced, friendly staff and state-of-the-art equipment to ensure that our patients undergo a stress-free and comfortable prostate cancer treatment.
Contact us to learn more.
1 Klein, E. Cleveland Clinic Localized Prostate Cancer Registry. In low-risk prostate cancer, quality of life is key to treatment choice. Urology Times, August 1, 2008.
2 Bittner, Net al. Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer. Oncology. August 2008, p. 995-1017.
3 Moran BJ, Gurel MH, Visockis J, Geary P. Post-operative pain and prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 54: Issue 2 Supplement 0.
4 Feigenberg SJ, Lee WR, Desilvio ML, et alL Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):956-64.
5 Steineck G, Helgesen F, Adolfsson J, et al: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002 Sep 12;347(11):790-6.
6 Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1063-8.
7 Frank, SJ et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007 Jun;177(6) 2151-6.
8 Zelefsky MJ, Fuks Z, Hunt M, et al: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1111-6.
9 Rassweiler J, Hruza M, Teber D, et al: Laparoscopic and robotic assisted radical prostatectomy–critical analysis of the results. Eur Urol. 2006 Apr;49(4):612-24
10 Quang et al. Technologic evolution in the treatment of prostate cancer. Oncology (21) 13. 1598-1603.